Synergistic anti-glioma effect of a coloaded nano-drug delivery system

Xu, Huae; Feng, Jia; Singh, Pankaj Kumar; Ruan, Shu; Zhang, Hao; Li, Xin

doi:10.2147/ijn.s116367

Cited by 25 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The co-delivery of both drugs also resulted in a more efficient tumor growth inhibition than the combination of both free drugs, or each drug alone. The attained results proved that the dual-delivery of these drugs could be a suitable strategy for glioblastoma therapy ( Xu et al, 2017 ).…”

Section: Glioma Tumorsmentioning

confidence: 85%

Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment

et al. 2018

View full text Add to dashboard Cite

Resveratrol (RES) is a natural polyphenolic non-flavonoid compound present in grapes, mulberries, peanuts, rhubarb and in several other plants. Numerous health effects have been related with its intake, such as anti-carcinogenic, anti-inflammatory and brain protective effects. The neuroprotective effects of RES in neurological diseases, such as Alzheimer’s (AD) and Parkinson’s (PD) diseases, are related to the protection of neurons against oxidative damage and toxicity, and to the prevention of apoptotic neuronal death. In brain cancer, RES induces cell apoptotic death and inhibits angiogenesis and tumor invasion. Despite its great potential as therapeutic agent for the treatment of several diseases, RES exhibits some limitations. It has poor water solubility and it is chemically instable, being degraded by isomerization once exposed to high temperatures, pH changes, UV light, or certain types of enzymes. Thus, RES has low bioavailability, limiting its biological and pharmacological benefits. To overcome these limitations, RES can be delivered by nanocarriers. This field of nanomedicine studies how the drug administration, pharmacokinetics, and pharmacodynamics are affected by the use of nanosized materials. The role of nanotechnology, in the prevention and treatment of neurological diseases, arises from the necessity to mask the physicochemical properties of therapeutic drugs to prolong the half-life and to be able to cross the blood–brain barrier (BBB). This can be achieved by encapsulating the drug in a nanoparticle (NP), which can be made of different kinds of materials. An increasing trend to encapsulate and direct RES to the brain has been observed. RES has been encapsulated in many different types of nanosystems, as liposomes, lipid and polymeric NPs. Furthermore, some of these nanocarriers have been modified with targeting molecules able to recognize the brain areas. Then, this article aims to overview the RES benefits and limitations in the treatment of neurological diseases, as the different nanotechnology strategies to overcome these limitations.

show abstract

Section: Glioma Tumorsmentioning

confidence: 85%

Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment

et al. 2018

View full text Add to dashboard Cite

show abstract

“…19,20 Fortunately, this setback could be partly reduced by modifying the surface of the complex with PEG, which can adjust the particle size, prevent them from aggregating, and further facilitate the steric stability of miRNAs payloads and uptake by target cells. 21,22 More recently, researchers have developed liposomes with PEG coating as an miRNA delivery vehicle that can penetrate the blood-brain barrier and target glioma cells. 23 Our authors have previously reported that a combination of SPION (superparamagnetic iron oxide nanoparticles) and FA (folate) based on mPEG-g-PEI nanoparticle shows great theranostic potential regarding combined gene therapy and MRI diagnosis in hepatocellular carcinoma which provides the possibility to deliver miRNA into glioma cells.…”

mentioning

confidence: 99%

Antitumor effect of a new nano-vector with miRNA-135a on malignant glioma

Liang

Sun²,

et al. 2017

IJN

View full text Add to dashboard Cite

Introduction MiR-135a is found to selectively induce apoptosis in glioma cell but not in normal neurons and glial cells. However, low transfection efficacy limits its application in vivo as other miRNAs. We prepared a new kind of nano-vector based on polyethylene glycol methyl ether (mPEG) and hyper-branched polyethylenimine (hy-PEI) in order to improve the miRNA delivery system into the glioma cells. Methods The mPEG-g-PEI/miR-135a was constructed and detected by 1 H NMR and FTIR analyses. Transmission electron microscope was utilized for its characteristics. Stability and release efficiency was assessed by electrophoresis. Biocompatibility was observed and analyzed through co-culture with astrocytes and malignant glioma cells (C6). Transfection rate was monitored by laser confocal microscopy and flow cytometry. The antitumor effect of mPEG-g-PEI/miR-135a to C6 was confirmed in vivo by MR scanning, pathology and survival curve. RT-PCR was used to assay transfection efficiency of mPEG-g-PEI/miR-135a in vitro and in vivo. And Western blotting was used to assess the expressions of the targeted proteins of miR-135a. Results In this experiment, we found the optimal N/P ratio of mPEG-g-PEI/miR-135a was about 6 judged by Zeta potential, particle size and encapsulation ability. The stability of mPEG-g-PEI/miR-135a in serum and the release efficiency in acid(pH=5.0) of mPEG-g-PEI/miR-135a were simulated the environment in vivo and in tumor. The mPEG-g-PEI nano-vector was co-cultured with malignant glioma cell C6 and normal astrocytes in vitro and showed good biocompatibility evaluated by CCK8 assay. The cell experiments in vitro indicated that mPEG-g-PEI could significantly improve miR-135a transfection by enhancing uptake effect of both normal glial and glioma cells. Given the C6 implanted in situ model, we discovered that the mPEG-g-PEI/miR-135a could obviously increase the survival period and inhibit the growth of glioma confirmed by MRI and histochemistry. In addition, the transfection efficiency of mPEG-g-PEI was better than that of other transfection agents either in vitro or in vivo confirmed by RT-PCR. Moreover, the expressions of the targeted proteins of miR-135a were consistent with the in vitro results. Conclusion These results suggest that mPEG-g-PEI is expected to provide a new effective intracellular miRNA delivery system with low toxicity for glioma therapy.

show abstract

“…The combination of encapsulated drugs also inhibited U87 cells migration in a major extent than free TEM/RVS. In the in vivo xenograft model, co-encapsulated TEM/RVS showed a stronger tumor growth inhibition compared to free TEM/RVS and control group, without any significant weight loss [53].…”

Section: Stilbenes: Resveratrolmentioning

confidence: 89%

Berries polyphenols: Nano-delivery systems to improve their potential in cancer therapy

Forbes‐Hernández

2020

JBR

View full text Add to dashboard Cite

Berries bioactive compounds, specially polyphenols, have been widely recognized for their chemopreventive and chemotherapeutic properties. However, most of them struggle with chemical instability, low solubility, extensive metabolism and consequently poor bioavailability, which limit their clinical use. An effective strategy to overcome such problems consists of the nano-delivery systems. In the present review, the progress made in utilization of nano-carriers for berries polyphenols administration either alone or in combination with chemotherapeutic drugs have been summarized.

show abstract

Synergistic anti-glioma effect of a coloaded nano-drug delivery system

Cited by 25 publications

References 31 publications

Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment

Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment

Antitumor effect of a new nano-vector with miRNA-135a on malignant glioma

Berries polyphenols: Nano-delivery systems to improve their potential in cancer therapy

Contact Info

Product

Resources

About